Avastin Stakes Claim In Ovarian Cancer; Other Ovarian Updates At ESMO Are Mixed

Roche is gearing up for a planned year-end submission of Avastin in advanced ovarian cancer in the EU after making a splash at the European Society for Medical Oncology meeting with updated data from its Phase III ICON7 study showing a progression-free survival benefit.